Jazz Pharmaceuticals appoints vice president of r&d
Jeffrey Tobias also takes chief medical officer role
Tobias has 20 years of experience in the biopharmaceutical industry across all phases of drug development, including regulatory filings in the US and Europe.
He has broad experience with a variety of therapeutic products spanning numerous clinical areas, including pain and neurological disorders.
Most recently, he was executive vice president of research and development at NeurogesX, where he has also been chief medical officer since 2005.
Prior to this Tobias was managing director of an independent biopharmaceutical consulting firm from 1996 to 2006, where he supported clients in all aspects of clinical development, technology assessment and strategic planning. He has also served in various roles in drug discovery and clinical development at ALZA, Chiron and XOMA.
Tobias also has 10 years of experience in clinical and academic medicine, focusing on internal and pulmonary and critical care medicine.
You may also like
Pharmaceutical
Ardena strengthens executive team to drive its next phase of growth
Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally
Pharmaceutical
Backed by investments exceeding $1 billion, PCI Pharma Services announces major expansion of US sterile fill-finish and drug-device delivery combination capabilities
As pharma manufacturers prioritise US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging